losec tablet (delayed-release)
cheplapharm arzneimittel gmbh - omeprazole (omeprazole magnesium) - tablet (delayed-release) - 20mg - omeprazole (omeprazole magnesium) 20mg - proton-pump inhibitors
suprefact solution
cheplapharm arzneimittel gmbh - buserelin (buserelin acetate) - solution - 100mcg - buserelin (buserelin acetate) 100mcg - antineoplastic agents
suprefact solution
cheplapharm arzneimittel gmbh - buserelin (buserelin acetate) - solution - 1mg - buserelin (buserelin acetate) 1mg - antineoplastic agents
visudyne powder for solution
cheplapharm arzneimittel gmbh - verteporfin - powder for solution - 15mg - verteporfin 15mg - eent drugs, miscellaneous
losec mups tablet (delayed-release)
cheplapharm arzneimittel gmbh - omeprazole (omeprazole magnesium) - tablet (delayed-release) - 10mg - omeprazole (omeprazole magnesium) 10mg - proton-pump inhibitors
losec mups tablet (delayed-release)
cheplapharm arzneimittel gmbh - omeprazole (omeprazole magnesium) - tablet (delayed-release) - 20mg - omeprazole (omeprazole magnesium) 20mg - proton-pump inhibitors
eucardic 12.5 mg tablets
cheplapharm arzneimittel gmbh - carvedilol - tablet - 12.5 milligram(s) - alpha and beta blocking agents; carvedilol
eucardic 25 mg tablets
cheplapharm arzneimittel gmbh - carvedilol - tablet - 25 milligram(s) - alpha and beta blocking agents; carvedilol
eucardic 6.25 mg tablets
cheplapharm arzneimittel gmbh - carvedilol - tablet - 6.25 milligram(s) - alpha and beta blocking agents; carvedilol
xeloda
cheplapharm arzneimittel gmbh - capecitabine - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastic agents - xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukes' stage c) colon cancer.xeloda is indicated for the treatment of metastatic colorectal cancer.xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. xeloda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.